Click here to access the full blog
- GMAWS is effective in managing alcohol withdrawal syndrome (AWS).
- The 2025 revised guidance allows easier estimation of alcohol units consumed.
- The Fast Alcohol Screening Tool (FAST) score is used to assess use disorder: a score of 5 or more suggests alcohol dependency.
- Prevention and treatment of Wernicke’s encephalopathy refers to ‘Vitamins B&C solution’ for intravenous infusion. Pabrinex® is no longer routinely available.
- The treatment of those at risk of Wernicke’s encephalopathy has been simplified.
- Oral thiamine should be continued for at least 6 weeks after becoming abstinent and having established a satisfactory diet. At that point thiamine discontinuation should be considered.
- Senior medical review of diagnosis and the need for possible adjunctive therapy if the patient:
- requires more than 120mg diazepam (or 12mg lorazepam) in 24 hours or
- is requiring full dose treatment 96 hours after last alcohol ingestion.
- Alterations to AWS treatment for patients with liver disease have been more clearly defined (see further details in Background section):
- All patients with evidence of advanced liver disease (cirrhosis) use symptom triggered treatment only.
- Patients with evidence of advanced liver disease and liver dysfunction: jaundice (bilirubin >80micromol/l), coagulopathy (INR/Prothrombin time ratio >1.5) or history of hepatic encephalopathy: use symptom triggered lorazepam: 1mg-2mg.